CD274 and non-small cell lung carcinoma: Overall, this study suggests that EVs-miR-625-5p might represent a novel biomarker to stratify patients affected by NSCLC treated with ICIs (nivolumab and pembrolizumab as monotherapy), in particular those with PD-L1 expression ≥50%.